Switch theme
Sign up to access all valuation multiples
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
1989
357
LTM Revenue $257M
LTM EBITDA $61.8M
$2.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vericel has a last 12-month revenue (LTM) of $257M and a last 12-month EBITDA of $61.8M.
In the most recent fiscal year, Vericel achieved revenue of $237M and an EBITDA of $16.6M.
Vericel expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vericel valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $257M | XXX | $237M | XXX | XXX | XXX |
| Gross Profit | $188M | XXX | $172M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $61.8M | XXX | $16.6M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 7% | XXX | XXX | XXX |
| EBIT | $7.4M | XXX | $4.5M | XXX | XXX | XXX |
| EBIT Margin | 3% | XXX | 2% | XXX | XXX | XXX |
| Net Profit | $11.5M | XXX | $10.4M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 4% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Vericel's stock price is $41.
Vericel has current market cap of $2.1B, and EV of $2.1B.
See Vericel trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1B | $2.1B | XXX | XXX | XXX | XXX | $0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Vericel has market cap of $2.1B and EV of $2.1B.
Vericel's trades at 8.7x EV/Revenue multiple, and 124.2x EV/EBITDA.
Equity research analysts estimate Vericel's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vericel has a P/E ratio of 180.4x.
See valuation multiples for Vericel and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV/Revenue | 8.0x | XXX | 8.7x | XXX | XXX | XXX |
| EV/EBITDA | 33.4x | XXX | 124.2x | XXX | XXX | XXX |
| EV/EBIT | 278.4x | XXX | 457.0x | XXX | XXX | XXX |
| EV/Gross Profit | 11.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 180.4x | XXX | 200.6x | XXX | XXX | XXX |
| EV/FCF | 212.1x | XXX | -355.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVericel's last 12 month revenue growth is 22%
Vericel's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.5M for the same period.
Vericel's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vericel's rule of X is 80% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vericel and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | 37% | XXX | 407% | XXX | XXX | XXX |
| Rule of 40 | 24% | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 80% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 71% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vericel acquired XXX companies to date.
Last acquisition by Vericel was XXXXXXXX, XXXXX XXXXX XXXXXX . Vericel acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vericel founded? | Vericel was founded in 1989. |
| Where is Vericel headquartered? | Vericel is headquartered in United States of America. |
| How many employees does Vericel have? | As of today, Vericel has 357 employees. |
| Who is the CEO of Vericel? | Vericel's CEO is Mr. Dominick C. Colangelo. |
| Is Vericel publicy listed? | Yes, Vericel is a public company listed on NAS. |
| What is the stock symbol of Vericel? | Vericel trades under VCEL ticker. |
| When did Vericel go public? | Vericel went public in 1997. |
| Who are competitors of Vericel? | Similar companies to Vericel include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Vericel? | Vericel's current market cap is $2.1B |
| What is the current revenue of Vericel? | Vericel's last 12 months revenue is $257M. |
| What is the current revenue growth of Vericel? | Vericel revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of Vericel? | Current revenue multiple of Vericel is 8.0x. |
| Is Vericel profitable? | Yes, Vericel is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Vericel? | Vericel's last 12 months EBITDA is $61.8M. |
| What is Vericel's EBITDA margin? | Vericel's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Vericel? | Current EBITDA multiple of Vericel is 33.4x. |
| What is the current FCF of Vericel? | Vericel's last 12 months FCF is $9.7M. |
| What is Vericel's FCF margin? | Vericel's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Vericel? | Current FCF multiple of Vericel is 212.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
